Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Thorne
University of Pittsburgh at Pittsburgh, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Western Oncolytics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This R01 funds animal research that includes an aim related to the TRIF gene. The FCOI arises with this research due to Dr. Thorne’s
ownership interest in Western Oncolytics, in addition to his financial interest as an inventor of intellectual property licensed by the University of Pittsburgh to the company, which involves the TRIF and HPGD genes.
Creation of Immuno-Oncolytic Viruses for Cancer Therapy
As the therapeutic potential of oncolytic viruses has been revealed in successful Phase II & III testing, it has become clear that a key and under-developed component of their therapeutic effect is the induction of a potent anti-tumor immune response. We believe that certain alterations in the backbone of oncolytic viruses such as those based on vaccinia virus will result in significantly enhanced immunotherapeutic and in situ vaccination potential without reducing their direct oncolytic effects. The effects of these alterations will be tested in vitro using primary human cells and tumors and in vivo using immunocompetent mice tumor models in order to develop next generation oncolytic vectors.
Filed on July 31, 2014.
Tell us what you know about Stephen Thorne's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephen Thorne filed other conflict of interest disclosures with the NIH:
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
Stephen Thorne | University of Pittsburgh at Pittsburgh | Conflict of Interest | Western Oncolytics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.